# OnCo record nct07730489 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct07730489/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct07730489", "NCT07730489" ;
  schema:name "A Study Comparing BL-M07D1 With Physician's Choice Therapy in Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Failed Prior Treatment With Oxaliplatin, F"@en ;
  schema:description "A phase 3 trial of trastuzumab brengitecan, regorafenib, fruquintinib and trifluridine/tipiracil in colorectal cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., not yet recruiting."@en ;
  schema:url <https://onco.cc/trials/nct07730489/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07730489> ;
  onco:status "planned" ;
  onco:tag "ctgov-ingest", "colorectal-deep-dive" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/rectal-cancer/>, <https://onco.cc/cancers/colon-cancer/>, <https://onco.cc/cancers/her2-amplified-colorectal/> ;
  onco:technologies <https://onco.cc/technologies/antiangiogenic/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/trastuzumab-brengitecan/>, <https://onco.cc/drugs/regorafenib/>, <https://onco.cc/drugs/fruquintinib/>, <https://onco.cc/drugs/trifluridine-tipiracil/> ;
  onco:companies <https://onco.cc/companies/systimmune/> .